[A case of the long-term survivor of rectal cancer who suffered from successive metastases to ovarium, peritoneum, liver, bone and para-aortic lymphonode].

A 37-year-old female, who had undergone a low anterior resection for lower rectal cancer, had been received chemotherapy (FOLFOX4, FOLFIRI) for 2 years because of right ovarian metastasis occurred and removed 9 months after the first operation. One month after 2 years of continued chemotherapy, progressive metastases happened to occur successively (rt lunge, left ovarium, liver, para-aortic lymphonode, Virchow lymphonode and bone). Right upper lobe pnemonectomy was performed first, then, peritonectomy, total hysterectomy with left oophorectomy and a partial resection of the small bowel were done.

Developing the social distress scale for head and neck cancer outpatients in Japan.

Objective: This study assessed the factor structure, internal consistency, and concurrent and discriminant validity of a scale used to measure social distress in Japanese head and neck cancer outpatients with facial disfigurement.

Method: The sample included 225 Japanese outpatients with head and neck cancer, including 129 patients with facial disfigurement. Participants' level of social distress was assessed through our scale, the European Organization for Research and Treatment Cancer questionnaire (EORTC) QLQ-H&N35 and the Hospital Anxiety and Depression scale (HADS).

[Three cases of gastric cancer treated by S-1 combined with docetaxel in place of cisplatin].

Although combination of S-1 and cisplatin (CDDP) is a standard therapy for advance or recurrent gastric cancer patients, there are some cases where a CDDP administration is difficult for patients. We here report three such cases of gastric cancer treated by S-1 and docetaxel (DOC) combination therapy. Based on our three cases, we believe that S-1 and DOC combination therapy could be suitable for outpatients showing safety and efficacy.

[A case report of un-resectable pancreas body carcinoma successfully treated by chemoradiotherapy].

We report a case of unresectable pancreatic cancer who survived for 29 months after a successful treatment by concurrent chemo-radiotherapy by gemcitabine and systemic administration of gemcitabine. A 65-year-old woman who was diagnosed as unresectable pancreas body cancer received concurrent chemo (gemcitabine 800 mg/body/w) -radiotherapy (1.8x30 Gy) and systemic chemotherapy (gemcitabine 1,000 mg/body/w) at an outpatient clinic.